Table 1 A summary of EZH2’s role in different cancers
From: The long and short non-coding RNAs modulating EZH2 signaling in cancer
Cancer type | Signaling network | Remarks | References |
|---|---|---|---|
Breast cancer | EZH2/PP2A | EZH2 reduces expression level of PP2A via triggering histone modification Conferring resistance to HER2 inhibitors | [59] |
Breast cancer | PRMT1/EZH2 | Tumor-associated macrophages stimulate PRMT1 expression to enhance EZH2 stability and expression, leading to breast cancer invasion | [60] |
Triple-negative breast cancer | EZH2/DLC1 | Curcumin impairs metastasis and proliferation of cancer cells Curcumin induces apoptosis Reducing EZH2 expression and subsequent upregulation of DLC1 | [61] |
Non-small cell lung cancer | EZH2/TGFBR2 | Synergistic impact between EZH2 and YAP/TAZ in transcription repression of TGFBR2 and promoting cancer progression | [62] |
Lung cancer | – | Association of EZH2 overexpression with cancer proliferation, metastasis, and therapy resistance Providing poor prognosis | [63] |
Colorectal cancer | DUXAP8/EZH2/EMT | Enhancing metastasis of cancer cells via EMT induction Activation of EZH2 by DUXAP8 is vital for EMT stimulation | [64] |
Colon cancer | – | Overexpression of EZH2 in colon cancer compared to normal colonic mucosa Reduced tumor differentiation, and lymph node metastasis Association with lower survival Therefore, EZH2 can be considered as a prognostic factor | [65] |
Ovarian cancer | EZH2/DAB2IP | DAB2IP overexpression suppresses cancer stem cell features in ovarian cancer EZH2 down-regulates DAB2IP expression to induce Wnt signaling, leading to ovarian cancer progression | [66] |
Gastric cancer | EZH2/Rho/ROCK/EMT | EZH2 promotes cancer metastasis via inducing Rho/ROCK-mediated EMT Diosgenin and GSK126 synergistically down-regulate EZH2 in suppressing cancer metastasis | [67] |
Prostate cancer | AR/EZH2 | The interaction between AR and EZH2 leads to prostate cancer progression EZH2 inhibition enhances anti-tumor activity of metformin | [68] |